Your browser is no longer supported. Please, upgrade your browser.
Arbutus Biopharma Corporation
Index- P/E- EPS (ttm)-1.24 Insider Own1.60% Shs Outstand79.49M Perf Week0.50%
Market Cap354.46M Forward P/E- EPS next Y-0.83 Insider Trans-4.11% Shs Float63.55M Perf Month-4.71%
Income-83.20M PEG- EPS next Q-0.23 Inst Own31.00% Short Float7.58% Perf Quarter45.16%
Sales6.10M P/S58.11 EPS this Y-137.80% Inst Trans-0.41% Short Ratio1.41 Perf Half Y-34.68%
Book/sh-0.62 P/B- EPS next Y15.30% ROA-76.20% Target Price- Perf Year29.81%
Cash/sh1.35 P/C3.00 EPS next 5Y- ROE128.90% 52W Range0.88 - 9.02 Perf YTD14.08%
Dividend- P/FCF- EPS past 5Y-9.90% ROI203.20% 52W High-55.10% Beta3.08
Dividend %- Quick Ratio15.90 Sales past 5Y-16.70% Gross Margin- 52W Low360.23% ATR0.37
Employees80 Current Ratio15.90 Sales Q/Q-51.60% Oper. Margin- RSI (14)52.67 Volatility6.93% 7.56%
OptionableYes Debt/Eq- EPS Q/Q81.70% Profit Margin- Rel Volume0.49 Prev Close3.96
ShortableYes LT Debt/Eq- EarningsNov 05 BMO Payout- Avg Volume3.41M Price4.05
Recom2.00 SMA204.61% SMA504.36% SMA20042.39% Volume1,665,268 Change2.27%
Dec-17-20Initiated H.C. Wainwright Buy $10
Jul-27-20Resumed JMP Securities Mkt Outperform $10 → $8
Jul-24-20Downgrade Robert W. Baird Outperform → Neutral
May-19-20Upgrade Wedbush Neutral → Outperform
Mar-06-20Upgrade Chardan Capital Markets Neutral → Buy $5
Feb-20-20Initiated Robert W. Baird Outperform $8
Feb-05-20Upgrade JMP Securities Mkt Perform → Mkt Outperform $10
Oct-07-19Reiterated B. Riley FBR Buy $7 → $3
Oct-04-19Downgrade Chardan Capital Markets Buy → Neutral
Oct-16-18Upgrade B. Riley FBR Neutral → Buy $11.50 → $9
Oct-15-18Upgrade Wedbush Underperform → Neutral $5
Oct-12-18Reiterated Chardan Capital Markets Buy $12 → $6.50
Jul-06-18Downgrade B. Riley FBR, Inc. Buy → Neutral $9 → $9
Mar-19-18Resumed Chardan Capital Markets Buy $8.25
Mar-19-18Downgrade Wedbush Outperform → Neutral $9 → $6
Jan-05-18Initiated B. Riley FBR, Inc. Buy $10
Apr-04-17Upgrade Chardan Capital Markets Neutral → Buy $3 → $6
Feb-01-17Reiterated Wedbush Outperform $13 → $10
Dec-13-16Downgrade Chardan Capital Markets Buy → Neutral $4 → $3
Nov-30-16Upgrade Chardan Capital Markets Neutral → Buy $4
Jan-04-21 08:00AM  
Dec-31-20 11:11PM  
Dec-15-20 08:52AM  
Dec-14-20 09:18AM  
Dec-12-20 04:02PM  
Dec-10-20 07:30AM  
Nov-16-20 07:00AM  
Nov-15-20 02:40PM  
Nov-12-20 08:32AM  
Nov-10-20 08:00AM  
Nov-07-20 07:06AM  
Nov-05-20 09:25AM  
Nov-04-20 09:21AM  
Oct-28-20 12:32PM  
Oct-16-20 06:01AM  
Oct-13-20 08:00AM  
Sep-28-20 08:00AM  
Sep-15-20 07:30AM  
Sep-09-20 08:00AM  
Aug-27-20 08:00AM  
Aug-26-20 08:40AM  
Aug-17-20 08:59AM  
Aug-12-20 11:27AM  
Aug-10-20 11:30AM  
Aug-07-20 08:55AM  
Aug-05-20 08:00AM  
Jul-31-20 12:30PM  
Jul-29-20 06:00PM  
Jul-27-20 12:31PM  
Jul-24-20 11:52PM  
Jul-23-20 05:39PM  
Jun-15-20 08:18PM  
May-27-20 08:00AM  
May-20-20 01:18PM  
May-19-20 11:11AM  
May-18-20 04:05PM  
May-15-20 11:04AM  
May-14-20 02:22PM  
May-12-20 08:00AM  
May-11-20 11:19AM  
May-04-20 08:00AM  
Apr-27-20 12:32PM  
Mar-31-20 08:47AM  
Mar-27-20 08:02AM  
Mar-26-20 04:05PM  
Mar-05-20 08:55AM  
Feb-27-20 12:30PM  
Feb-10-20 08:00AM  
Jan-02-20 05:05AM  
Dec-30-19 10:08AM  
Dec-27-19 09:04AM  
Dec-19-19 03:50PM  
Nov-06-19 09:35AM  
Nov-03-19 07:13AM  
Oct-30-19 10:33AM  
Oct-10-19 02:59PM  
Oct-04-19 07:32AM  
Oct-03-19 04:05PM  
Sep-26-19 07:30AM  
Sep-19-19 06:17AM  
Aug-20-19 04:05PM  
Aug-06-19 07:30AM  
Aug-05-19 08:55AM  
Jul-29-19 07:30AM  
Jul-25-19 10:34AM  
Jul-15-19 04:05PM  
Jul-04-19 04:09PM  
Jul-03-19 07:31AM  
Jul-02-19 04:01PM  
Jun-21-19 09:20AM  
Jun-20-19 07:30AM  
Jun-17-19 07:30AM  
Jun-13-19 08:30AM  
May-22-19 12:56PM  
May-13-19 08:30AM  
May-06-19 05:15PM  
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-836, a capsid inhibitor that has the potential to inhibit HBV replication by preventing the assembly of functional viral capsids; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease. Its RNAi HBV candidates are designed to reduce hepatitis B surface antigen expression in patients chronically infected with HBV. In addition, it develops AB-729, a second generation RNAi therapeutic targeted to hepatocytes; HBV RNA destabilizer, an orally active agent that cause the destabilization of HBV RNAs, which leads to RNA degradation and to reduction in HBsAg levels. Further, the company engages conducting a Phase 1a/1b clinical trial and several pre-clinical and investigational new drug-enabling studies to evaluate proprietary HBV therapeutic agents, together with standard of care therapies, and in combination with each other. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McElhaugh Michael J.Chief Business OfficerDec 14Sale5.0040,000200,0321,327,457Dec 16 04:33 PM
McElhaugh Michael J.Chief Business OfficerJul 23Sale5.0120,000100,2001,367,457Jul 27 05:27 PM